相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Martin Friedrichsen et al.
DIABETES OBESITY & METABOLISM (2021)
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean et al.
ENDOCRINE REVIEWS (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Rune V. Overgaard et al.
CLINICAL PHARMACOKINETICS (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
Lone B. Enebo et al.
LANCET (2021)
Functionally distinct POMC-expressing neuron subpopulations in hypothalamus revealed by intersectional targeting
Nasim Biglari et al.
NATURE NEUROSCIENCE (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Julie R. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism
Diba Borgmann et al.
CELL METABOLISM (2021)
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models
Tito Borner et al.
DIABETES (2021)
Development of Cagrilintide, a Long-Acting Amylin Analogue
Thomas Kruse et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
A genetic map of the mouse dorsal vagal complex and its role in obesity
Mette Q. Ludwig et al.
NATURE METABOLISM (2021)
Central and peripheral GLP-1 systems independently suppress eating
Daniel I. Brierley et al.
NATURE METABOLISM (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study
Maria Alba et al.
CLINICAL OBESITY (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study
Nicholas A. Di Prospero et al.
CLINICAL OBESITY (2021)
Twelve weeks of exenatide treatment increases [18F] fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males
Laura G. M. Janssen et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Advances in oral peptide therapeutics
Daniel J. Drucker
NATURE REVIEWS DRUG DISCOVERY (2020)
Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes
Huub J. van Eyk et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
Thomas A. Wadden et al.
OBESITY (2020)
GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats
Samantha M. Fortin et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
Julia Ast et al.
NATURE COMMUNICATIONS (2020)
GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function
Katharina Timper et al.
CELL METABOLISM (2020)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Obesity in adults: a clinical practice guideline
Sean Wharton et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)
Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide
Samantha M. Fortin et al.
PHYSIOLOGY & BEHAVIOR (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
Leptin receptor-expressing nucleus tractus solitarius neurons suppress food intake independently of GLP1 in mice
Wenwen Cheng et al.
JCI INSIGHT (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Glucagon-Like Peptide-1-, but not Growth and Differentiation Factor 15-, Receptor Activation Increases the Number of Interleukin-6-Expressing Cells in the External Lateral Parabrachial Nucleus
Fredrik Anesten et al.
NEUROENDOCRINOLOGY (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Youngmi Song et al.
CELL METABOLISM (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology
Ariana M. Chao et al.
OBESITY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food
Marie K. Holt et al.
DIABETES (2019)
Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight
L. Lopez-Ferreras et al.
MOLECULAR PSYCHIATRY (2018)
Glucagon-Like Peptide-1 Receptor Signaling in the Lateral Dorsal Tegmental Nucleus Regulates Energy Balance
David J. Reiner et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
Teayoun Kim et al.
DIABETES (2018)
Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons
Jessica M. Adams et al.
DIABETES (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
Melissa A. Burmeister et al.
DIABETES (2017)
Endogenous Glucagon-like Peptide-1 Receptor Signaling in the Nucleus Tractus Solitarius is Required for Food Intake Control
Amber L. Alhadeff et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux et al.
LANCET (2017)
Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus
Ji Liu et al.
NEURON (2017)
Paraventricular Thalamic Control of Food Intake and Reward: Role of Glucagon-Like Peptide-1 Receptor Signaling
Zhi Yi Ong et al.
NEUROPSYCHOPHARMACOLOGY (2017)
The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity
Melissa A. Burmeister et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Jean-Philippe Krieger et al.
DIABETES (2016)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
Role of lateral septum glucagon-like peptide 1 receptors in food intake
Sarah J. Terrill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2016)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects
Roy Eldor et al.
DIABETES CARE (2016)
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
A. Blackman et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance
David J. Reiner et al.
JOURNAL OF NEUROSCIENCE (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
Giuseppe Daniele et al.
DIABETES (2015)
Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms
S. E. Kanoski et al.
DIABETES OBESITY & METABOLISM (2015)
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
Jennifer S. ten Kulve et al.
DIABETOLOGIA (2015)
Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
Kristy M. Heppner et al.
ENDOCRINOLOGY (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Hippocampal GLP-1 Receptors Influence Food Intake, Meal Size, and Effort-Based Responding for Food through Volume Transmission
Ted M. Hsu et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System
Jennifer E. Richard et al.
PLOS ONE (2015)
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
Liselotte van Bloemendaal et al.
DIABETES (2014)
GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
Daniel Beiroa et al.
DIABETES (2014)
GLP-1 Receptor Stimulation of the Lateral Parabrachial Nucleus Reduces Food Intake: Neuroanatomical, Electrophysiological, and Behavioral Evidence
Jennifer E. Richard et al.
ENDOCRINOLOGY (2014)
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Anna Secher et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Glucagon-Like Peptide-1 Receptor Activation in the Nucleus Accumbens Core Suppresses Feeding by Increasing Glutamatergic AMPA/Kainate Signaling
Elizabeth G. Mietlicki-Baase et al.
JOURNAL OF NEUROSCIENCE (2014)
Glucagon-Like Peptide-1 Receptor Signaling in the Lateral Parabrachial Nucleus Contributes to the Control of Food Intake and Motivation to Feed
Amber L. Alhadeff et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt
Laura E. Rupprecht et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
Mohammad Hossein Noyan-Ashraf et al.
CIRCULATION (2013)
Combination of Obesity and High-Fat Feeding Diminishes Sensitivity to GLP-1R Agonist Exendin-4
Frank A. Duca et al.
DIABETES (2013)
Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity
Haiko Schlogl et al.
DIABETES CARE (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala
J. A. Parker et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6
Rozita Shirazi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling
Sarah H. Lockie et al.
DIABETES (2012)
Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner
S. Zhao et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1
James T. Patterson et al.
ACS CHEMICAL BIOLOGY (2011)
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Elena-Dana Baraboi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)
Intracellular Signals Mediating the Food Intake-Suppressive Effects of Hindbrain Glucagon-like Peptide-1 Receptor Activation
Matthew R. Hayes et al.
CELL METABOLISM (2011)
The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans
Akila De Silva et al.
CELL METABOLISM (2011)
Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Scott E. Kanoski et al.
ENDOCRINOLOGY (2011)
Hyperphagia and Increased Fat Accumulation in Two Models of Chronic CNS Glucagon-Like Peptide-1 Loss of Function
Jason G. Barrera et al.
JOURNAL OF NEUROSCIENCE (2011)
Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
Amanda M. Dossat et al.
JOURNAL OF NEUROSCIENCE (2011)
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Alessandro Pocai et al.
DIABETES (2009)
Endogenous Hindbrain Glucagon-Like Peptide-1 Receptor Activation Contributes to the Control of Food Intake by Mediating Gastric Satiation Signaling
Matthew R. Hayes et al.
ENDOCRINOLOGY (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Eric Ravussin et al.
OBESITY (2009)
The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Christine Longuet et al.
CELL METABOLISM (2008)
Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation
Matthew R. Hayes et al.
ENDOCRINOLOGY (2008)
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Tanya Hansotia et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K. Wynne et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation
Diana L. Williams et al.
DIABETES (2006)
分享论文
